FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:813 September 9, 1993 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Maguire, J. H.

To the Editor: Case 8-1993 (Feb. 25 issue)¹ describes a patient with subarachnoid cysticercosis who was treated with praziquantel without the simultaneous administration of glucocorticoids. This approach contrasts with that currently recommended for the management of this form of the disease². Although both praziquantel and albendazole are effective against parenchymal brain cysticerci, the latter is the drug of choice for subarachnoid cysts³. Albendazole and praziquantel have different mechanisms of action. Praziquantel destroys the scolex of the cysticercus by producing spastic paralysis of the parasite's musculature. In contrast, albendazole inhibits the uptake of glucose by parasitic membranes, causing energy . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.